image dons

I make a donation

ACORES-2

The objective of the ACORES-2 trial is to evaluate the effect of RAS blockers discontinuation versus continuation on clinical course of patients infected with COVID-19.

En cours

Colloquium : Pathologies cardiaques de la femme (15 novembre 2022)
Présentations en ligne !!!

logo étude

objectif

Evaluate the effect of RAS blockers discontinuation versus continuation on clinical course of patients infected with COVID-19.

date de réalisation

2020

nombre de patients

554

nombre de centres participants

12 french sites

type de financement

Public (APHP)

Référence

NCT04329195

ACE Inhibitors or ARBs Discontinuation for Clinical Outcome Risk Reduction in Patients Hospitalized for the Endemic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection : the Randomized ACORES-2 Study

Since December 2019, a novel coronavirus called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has caused an international outbreak of respiratory illness described as COVID-19.
Individuals with a history of cardiovascular disease develop a more severe illness and have higher rates of death.
Because of the potential interaction between RAS blockers and SARS-CoV-2 mechanism of infection, there are ongoing scientific discussions on whether they should be stopped or continued in patients with COVID-19.
It is crucial to determine whether RAS blockers should be discontinued or not in patients with COVID-19.

Autres études

+

ANCHOR

En cours


Demonstrate the superiority of an association of VA-ECMO and IABP with an optimal medical treatment compared with an optimal medical treatment only in cardiogenic shock AMI patients
+

AFLOAT

En cours


To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.
+

ARCACHON

En cours


To demonstrate the non-inferiority of a strategy of simple clinical follow-up (without non-invasive stress testing) in asymptomatic CAD patients with a prior history of coronary revascularization comp...